Amir S Steinberg, MD Email Amir Steinberg
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
- Cancer (Oncology)
- Hospital Affiliation
- The Mount Sinai Hospital
- Ruttenberg Treatment Center 212-241-6021212-241-6021
Amir Steinberg, MD, FACP, is an associate professor in the division of hematology-oncology at Mount Sinai Hospital. Dr. Steinberg's primary areas of focus are the hematologic malignancies and stem cell transplantation. He has a clinical interest in cancer survivorship as he is a lymphoma survivor himself. He was the site-specific principal investigator of a multicenter Hodgkin lymphoma study looking at the use of brentuximab in front-line therapy of newly diagnosed patients. He is also a co-investigator on several studies focused on transplant and the hematologic malignancies, particularly lymphoma.
In addition to his focus on hematologic malignancies, Dr. Steinberg is the lead investigator in studies exploring transplant in nonmalignant conditions. One study is on autologous stem cell transplant for Crohn's Disease for which he collaborates closely with Mt. Sinai's Inflammatory Bowel Disease group. The other study sis comparing allogeneic transplant for sickle cell anemia with standard of care measures and he collaborates closely with Mt. Sinai's sickle cell anemia team for this study. He also sees referral for other such nonmalignant conditions such as myasthenia gravis and scleroderma.
He was previously a clinical assistant professor at UCLA on the staff of Cedars-Sinai Medical Center in Los Angeles where his research focused on nonmyeloablative stem cell transplants for acute leukemia and novel therapies for relapsed central nervous system lymphomas.
Dr. Steinberg grew up in Texas and graduated magna cum laude from the University of Texas, Austin, with a bachelor's in history and a minor in biology. He earned his medical degree from Texas Tech University School of Medicine, and he completed his residency in internal medicine at St. Luke's and Roosevelt Hospitals (previously teaching hospitals of Columbia University) which are now both members of the Mt. Sinai Hospital System. Dr. Steinberg completed a fellowship in hematology-oncology at Lenox Hill Hospital. Subsequently, Dr. Steinberg completed a bone marrow transplant fellowship at Stanford University Hospital and Clinics in Palo Alto, California. Dr. Steinberg is board-certified in Medical Oncology, Hematology, and Internal Medicine.
- Acute Lymphoid Leukemia
- Acute Myeloid Leukemia
- Adult Non-Hodgkin's Lymphoma
- Bone Marrow Transplantation
- Bone Marrow Transplantation, Allogeneic
- Bone Marrow Transplantation, Autologous
- Cancer Survivorship
- Clinical Trials
- Hematologic Malignancies
- Hodgkin's Disease
- Hodgkin's Lymphoma
- LGL Leukemia
- Mantle Cell Lymphoma
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Plasma Cell Neoplasms
- Primary Central Nervous System Lymphoma
- Waldenström's Macroglobulinemia
BA,, the University of Texas,
MD,, Texas Tech University School of Medicine,
MD, Texas Tech Univ. Health Science Ctr
Residency, Internal Medicine
St. Lukes Roosevelt Hospital
Lenox Hill Hospital
Fellowship, Bone Marrow Trans.
Stanford University Hospital
Fellow of the American College of Physicians (FACP)
American College of Physicians (ACP)
In Recognition of Contributions to ACP and to field of Medicine
Award of Excellence,
Southern California Cancer Pain Initiative,
In Recognition of Effort to Lessen Pain in Cancer Patients,
Dr. Steinberg is the principal investigator of a Hodgkin lymphoma study looking at the use of brentuximab in front-line therapy of newly diagnosed patients. He is also a co-investigator on several studies focused on transplant and the hematologic malignancies, particularly lymphoma.
Steinberg A, Asher A, Bailey C, Fu JB. The role of physical rehabilitation in stem cell transplantation patients. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2015 May;.
Steinberg A, Gorman E, Tannenbaum J. Thiamine deficiency in stem cell transplant patients: a case series with an accompanying review of the literature. Clinical lymphoma, myeloma & leukemia 2014 Sep; 14 Suppl.
Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2015 Jan; 21(1).
Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, Burns LJ, Cahn JY, Duncan C, Hale GA, Halter J, Hayashi RJ, Hsu JW, Jacobsohn DA, Kamble RT, Kamani NR, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Myers KC, Ramanathan M, Saber W, Savani BN, Schouten HC, Socie G, Sorror ML, Steinberg A, Popat U, Wingard JR, Mattsson J, Majhail NS. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2014 Nov; 20(11).
Kim SS, Renteria AS, Steinberg A, Banoff K, Isola L. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma. Cytotherapy 2014 Nov; 16(11).
Masood A, Steinberg A, Moshier E, Malone A, Scigliano E, Nieto J, Osman K, Grosskreutz C, Isola L, Brody J. Retrospective analysis of prognosticators in patients with relapsed Hodgkin's Lymphoma treated with autologous transplant: results of a single center. Medical oncology (Northwood, London, England) 2013 Mar; 30(1).
Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, Chow R, Duncan C, Eldjerou LK, Gupta V, Hale GA, Halter J, Hayes-Lattin BM, Hsu JW, Jacobsohn DA, Kamble RT, Kasow KA, Lazarus HM, Mehta P, Myers KC, Parsons SK, Passweg JR, Pidala J, Reddy V, Sales-Bonfim CM, Savani BN, Seber A, Sorror ML, Steinberg A, Wood WA, Wall DA, Winiarski JH, Yu LC, Majhail NS. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2012 Dec; 18(12).
Pham A, Steinberg A, Kwok B, Lopez A, Lim S, Lill M. Precursor T-Cell acute lymphoblastic leukemia/lymphoma with rare presentation in the urinary bladder. Hematology reports 2011 Aug; 3(2).
Steinberg A, Kansal R, Wong M, Lopez A, Lim S, Lopategui J, Lill M. Good clinical response in a rare aggressive hematopoietic neoplasm: plasmacytoid dendritic cell leukemia with no cutaneous lesions responding to 4 donor lymphocyte infusions following transplant. Case reports in transplantation 2011; 2011.
Kim D, Kwok B, Steinberg A. Simultaneous acute myeloid leukemia and multiple myeloma successfully treated with allogeneic stem cell transplantation. Southern medical journal 2010 Dec; 103(12).
Pham A, Bahadini B, Alsabeh R, Steinberg A. First reported case of aplastic anemia occurring in a patient after acute promyelocytic leukemia in remission. Clinical advances in hematology & oncology : H&O 2009 Oct; 7(10).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Steinberg did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.